논문검색
Author Gun Hi Kang, M.D., Gwang Sil Kim, M.D., Hyo Rak Lee, M.D., Young Jin Yuh, M.D. and Sung Rok Kim, M.D.
Place of duty Department of Internal Medicine, College of Medicine, Inje University, Sanggye Paik Hospital, Seoul, Korea
Title A Phase II Trial of Paclitaxel, 5-fluorouracil (5-FU) and Cisplatin in Patients with Metastatic or Recurrent Gastric Cancer
Publicationinfo Cancer Res Treat 2008 Sep; 040(03): 106-110.
Key_word Stomach Neoplasms, Chemotherapy, Paclitaxel, 5-fluorouracil, Cisplatin
Full-Text
Abstract Purpose: We wanted to assess the effectiveness and safety of combination chemotherapy with paclitaxel, 5-fluorouracil (5-FU) and cisplatin for treating advanced gastric cancer. Materials and Methods: Patients with metastatic or recurrent gastric cancer were entered into this study. Paclitaxel at a dose of 135 mg/m2 on day 1, 5-FU 1 g/m2/ day in a 24 hour continuous infusion from day 1 to day 4 and cisplatin 60 mg/m2 on day 1 were administered. This regimen was repeated every 3 weeks. Results: A total of 34 patients were enrolled in this study. Among them, 33 patients were finally evaluable for their response. 17 (51.5%) patients had a partial response (95% CI: 26.0∼77.0%). The median duration of overall survival was 13.2 months. Grade 3 or 4 neutropenia and thrombocytopenia were observed in 15.2% and 1.1% of all the cycles, respectively. Grade 3 stomatitis and neurotoxicity were observed in 20.6% and 1.1% of all patients, respectively. Grade 4 non-hematologic toxicity was not observed. Conclusions: The regimen of paclitaxel, 5-FU and cisplatin demonstrated activity and accepatable toxicity for treating metastatic gastric cancer. (Cancer Res Treat. 2008;40:106-110)
출판정보 대한암학회지 2008 Sep; 040(03): 106-110.